Lyell Immunopharma LYEL Cash Flow Statement (2020-2026)

NASDAQ LYEL
$9.38 -0.03 (-0.32%)
As of: Oct 22, 2026 · 3:34 PM EDT
Reported Financials

Lyell Immunopharma Quarterly Cash Flow Statement

Periods 25 quarters
Latest Jun 2026

Lyell Immunopharma reported cash from operations of -$33.92M and free cash flow of -$34.18M for the quarter ended Jun 2026, up 1.6% year over year. This cash flow statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-48.88M-83.71M-68.14M-36.32M-70.25M-8.40M-66.96M-63.89M-50.85M-52.93M-60.67M-45.81M-44.58M-191.94M-52.20M-42.68M-38.85M-140.72M-24.15M-44.76M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
4.09M4.57M4.19M4.17M4.62M5.04M5.03M5.06M5.10M5.06M5.02M4.90M4.68M5.03M3.44M3.14M2.57M2.40M2.33M2.22M
Share-based CompensationStock Comp.
13.04M21.18M22.03M22.41M19.12M18.36M13.88M14.22M10.52M8.46M9.16M8.28M7.62M8.08M6.02M5.00M5.23M25.57M4.30M4.53M
Gains from Sales and DivestituresGains Divest
-0.21M-0.67M-0.08M-0.01M-0.01M-0.43M-0.64M-0.44M-0.02M-0.40M-0.92M-1.29M-2.47M0.25M0.17M-0.12M
Gains from Investment SecuritiesGains Investment
-5.00M-10.00M-2.92M12.92M1.54M-0.02M-0.03M0.00M0.00M0.00M
Asset Writedowns and ImpairmentWritedown
5.00M-5.00M13.00M38.30M1.44M
Other non-cash itemsOther Non-Cash
3.53M-18.28M-4.09M4.47M1.80M-4.69M-1.42M1.63M-2.18M1.06M1.34M-0.93M0.51M87.30M0.59M0.69M1.46M67.98M0.75M0.81M
Change in Working Capital
Change in Account PayablesChange Payables
-0.99M0.10M2.94M-1.77M0.02M-0.53M2.07M0.38M-1.41M0.43M-0.11M-0.52M-0.57M-2.04M-1.65M-0.23M-0.78M0.33M2.38M-1.46M
Change in Accured ExpensesChange Accured Exp.
1.94M4.22M-6.39M-0.77M1.32M5.37M-5.86M2.27M4.61M-1.74M-3.61M0.52M3.09M-1.25M-9.79M-3.33M0.57M4.90M-3.57M4.61M
Change in Other Operating AssetsOther Assets Change
1.87M0.18M0.40M-0.41M0.68M1.30M0.41M-1.05M0.66M-3.15M-0.60M0.84M1.62M-3.64M-2.00M-2.80M-0.42M2.39M-0.09M-3.24M
Change in Other Operating LiabilitiesOther Liabilities Change
12.32M1.71M3.51M-35.86M2.28M-45.42M-0.11M-0.11M-0.11M-0.11M-0.11M-0.11M0.13M-0.31M-0.11M-0.11M-0.35M-2.16M0.01M0.01M
Other Working Capital ChangesOther WC Changes
10.45M1.53M3.11M-35.45M1.60M-46.72M-0.52M0.94M-0.78M3.04M0.48M-0.95M-1.49M3.32M1.89M2.69M0.07M-4.56M0.10M3.25M
Cash from OperationsCash from Ops.
-25.49M-33.21M-47.85M-44.33M-37.10M-40.27M-46.21M-39.16M-37.69M-40.64M-42.02M-38.09M-35.04M-47.24M-54.74M-34.46M-28.58M-32.25M-38.51M-33.92M
Investing Activities
Capital ExpendituresCapex
11.60M10.27M9.73M7.17M2.79M4.58M1.53M0.93M0.20M0.03M0.03M0.33M0.06M0.04M0.25M0.17M0.06M0.30M0.09M0.26M
Sales of Property, Plant and EquipmentPP&E (Sale)
0.26M0.02M
Change in Property, Plant and EquipmentChange in PP&E
-11.60M-10.27M-9.73M-7.17M-2.79M-4.58M-1.53M-0.93M-0.20M-0.03M-0.03M-0.33M-0.06M-0.04M-0.25M-0.17M0.20M-0.28M-0.09M-0.26M
Purchase of InvestmentsInvestments Purchased
275.31M133.92M96.20M89.66M160.79M59.67M108.56M33.26M78.28M256.79M108.01M116.46M131.43M38.80M84.41M80.70M70.99M42.80M37.18M53.52M
Sale and Maturity of InvestmentsInvestments Sold
142.04M70.33M79.81M121.85M106.50M110.90M142.25M187.10M178.15M156.12M130.04M161.80M133.41M123.70M154.12M93.52M74.14M52.91M54.65M69.39M
Cash from Investing ActivitiesCash from Investing
-144.91M-73.86M-26.12M25.02M-57.09M46.65M32.15M152.91M99.67M-100.69M21.99M45.01M1.92M53.51M69.47M12.65M3.35M-31.37M17.38M15.62M
Financing Activities
Change in Capital Stock
Common Stock IssuedStock Issued
-0.53M7.40M2.56M2.46M5.13M0.96M1.25M0.07M0.88M0.10M0.86M0.44M0.18M50.00M0.22M0.03M0.52M
Net Shares Issued and RepurchasedNet Shares Issued
-0.53M7.40M2.56M2.46M5.13M0.96M1.25M0.07M0.88M0.10M0.86M0.44M0.18M50.00M0.22M0.03M0.52M
Net Equity Issued and RepurchasedNet Equity Issued
-0.53M7.40M2.56M2.46M5.13M0.96M1.25M0.07M0.88M0.10M0.86M0.44M0.18M50.00M0.22M0.03M0.52M
Other financing activitiesOther financing
-0.37M-0.09M-0.07M-0.05M-0.22M-0.12M-0.08M0.00M0.00M0.00M
Cash from Financing ActivitiesCash from Financing
-0.53M7.40M2.56M2.46M4.76M0.86M-0.07M1.20M-0.14M0.76M0.03M0.86M0.44M0.00M0.18M50.00M0.22M51.72M0.52M
Additional items
Change in Cash
-170.94M-99.68M-71.42M-16.86M-89.43M7.24M-14.13M114.95M61.84M-140.57M-20.00M7.78M-33.12M6.70M14.73M-21.63M24.77M-63.39M30.59M-17.78M
Ending Cash Balance
393.97M294.29M222.88M206.02M116.59M123.83M109.71M224.65M286.50M145.93M125.94M133.71M100.59M107.29M122.02M100.39M125.16M61.77M92.36M74.57M
Free Cash FlowFCF
-37.09M-43.48M-57.59M-51.50M-39.89M-44.85M-47.75M-40.09M-37.88M-40.66M-42.05M-38.43M-35.10M-47.29M-54.98M-34.63M-28.64M-32.56M-38.60M-34.18M
Net Cash FlowNCF
-170.94M-99.68M-71.42M-16.86M-89.43M7.24M-14.13M114.95M61.84M-140.57M-20.00M7.78M-33.12M6.70M14.73M-21.63M24.77M-63.39M30.59M-17.78M

Lyell Immunopharma Cash Flow Statement API

Pull Lyell Immunopharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=LYEL&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY